




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/37, C07K 13/00 A61K 39/12 // C12N 15/62	A1	(11) International Publication Number: WO 93/00436
		(43) International Publication Date: 7 January 1993 (07.01.93)
(21) International Application Number: PCT/GB92/01092		
(22) International Filing Date: 17 June 1992 (17.06.92)		
(30) Priority data: 9113809.9 26 June 1991 (26.06.91) GB		
(71) Applicant (for all designated States except US): CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED [GB/GB]; 2 Carlton House Terrace, London SW17 5AR (GB).	(74) Agent: McCALLUM, William, Potter; Cruikshank & Fairweather, 19 Royal Exchange Square, Glasgow G1 3AE (GB).	
(72) Inventors; and (75) Inventors/Applicants (for US only): JARRETT, William, Fleming, Hoggan [GB/GB]; 60 Netherblane, Blansfield, Glasgow G63 9JP (GB). CAMPO, Maria, Saveria [IT/GB]; 33 Clevedon Road, Glasgow G12 0PH (GB). SMITH, Kenneth, Thomas [GB/GB]; 45 Deepdene Road, Glasgow G61 1NS (GB).	(81) Designated States: AU, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE).	
	Published With international search report.	

(54) Title: PAPILLOMAVIRUS L2 PROTEIN

BPV-2

(57) Abstract

The L2 protein of papillomavirus (particularly BPV-2 and BPV-4) has been cloned as a fusion protein with beta-galactosidase and GST; both as the whole protein and as fragments. Vaccination of calves is found to have both a prophylactic effect in tumour prevention and a therapeutic effect in tumour regression.